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vmPFCStudies have revealed abnormalities in resting-state functional connectivity in those with major depressive
disorder speciﬁcally in areas such as the dorsal anterior cingulate, thalamus, amygdala, the pallidostriatum
and subgenual cingulate. However, the effect of antidepressant medications on human brain function is less
clear and the effect of these drugs on resting-state functional connectivity is unknown.
Forty volunteers matched for age and gender with no previous psychiatric history received either citalopram
(SSRI; selective serotonergic reuptake inhibitor), reboxetine (SNRI; selective noradrenergic reuptake
inhibitor) or placebo for 7 days in a double-blind design. Using resting-state functional magnetic resonance
imaging and seed based connectivity analysis we selected the right nucleus accumbens, the right amygdala,
the subgenual cingulate and the dorsal medial prefrontal cortex as seed regions. Mood and subjective
experience were also measured before and after drug administration using self-report scales.
Despite no differences in mood across the three groups, we found reduced connectivity between the amygdala
and the ventral medial prefrontal cortex in the citalopram group and the amygdala and the orbitofrontal cortex
for the reboxetine group. We also found reduced striatal–orbitofrontal cortex connectivity in the reboxetine
group.
These data suggest that antidepressant medications can decrease resting-state functional connectivity
independent of mood change and in areas known to mediate reward and emotional processing in the brain.
We conclude that hypothesis-driven seed based analysis of resting-state fMRI supports the proposition that
antidepressant medications might work by normalising the elevated resting-state functional connectivity seen
in depressed patients.Cabe).
 license.© 2011 Elsevier Inc. Open access under CC BY license.Introduction
Alterations in resting-state connectivity have been observed in
depression acrossmultiple networks. For example parts of the cognitive
control network (anterior cingulate, prefrontal cortex) which are
involved in decision making, attention and resolving conﬂicts have
been found to be altered in depression (Davidson et al., 2002; Fitzgerald
et al., 2006; Rogers et al., 2004; Schlosser et al., 2008; Siegle et al., 2007;
Vasic et al., 2009) as has the default mode network a network involved
in self-referential activity and emotional regulation (e.g. precuneus,
hippocampus, medial prefrontal cortex) (Buckner et al., 2008; Grimm
et al., 2011;Northoff et al.; Raichle et al., 2001;Raichle andSnyder, 2007;
Sheline et al., 2009) and parts of the affective network (orbitofrontal
cortex, striatum, amygdala) known to be involved in the processing of
emotional and rewarding information (Johansen-Berg et al., 2008;
Northoff et al.; Price and Drevets, 2009).Recently Sheline and colleagues reported increased dorsal medial
prefrontal cortex connectivity (dmPFC) in depression and suggested
that differences in default mode processing may contribute to
depression and thus may be a target for antidepressant drug treatment.
Consistent with this idea, recent research examining emotional
processing in depressed patients has also shown that dysfunctional
activity in these regions is attenuated after pharmacological treatment
and that this in turn correlateswith treatment response (DeRubeis et al.,
2005; Fu et al., 2004; Harmer et al., 2006; Hollon et al., 2005; Sheline
et al., 2001; Victor et al., 2010; Wagner et al., 2010). Furthermore a
recent study indepressedpatients examiningorbitofrontal cortex (OFC)
connectivity before and after antidepressant treatment found increased
OFC connectivityprior to treatmentdifferentiated responders fromnon-
responders (Lisiecka et al.).
Some preliminary examination of our resting-state dataset
revealed decreased connectivity between the dmPFC and hippocam-
pus following citalopram treatment compared to placebo (McCabe
et al., 2011). However, it is unknownwhether this is a general effect of
all antidepressants or speciﬁc to those with serotonergic action. Thus
we decided to investigate the dmPFC connectivity in the reboxetine
group and hypothesised that unlike citalopram, reboxetine would
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pathways have a role, such as the striatum and prefrontal cortex
(Eshel and Roiser; Mizoguchi et al., 2008; Valentini et al., 2004). We
also decided to examine other seed regions within the affective
network that we have shown in our previous studies to be modulated
by reboxetine and citalopram during task-based fMRI such as the
nucleus accumbens, the subgenual cingulate and the amygdala
(Harmer et al., 2009, 2004; McCabe et al., 2010; Norbury et al.,
2007). We investigated the effects in healthy volunteers with no
history of depression or use of psychiatric medications. We hypothe-
sised that antidepressant medications would decrease connectivity
within the affective network and that this would be consistent with
the recent hypotheses proposed by Sheline et al. (2010) and McCabe
et al. (2011).
The time course of the current study (7 days) was limited
compared to the duration of clinical treatment with antidepressants
and it would therefore also be relevant to study the effect of
medications on the neural basis of resting-state after longer treatment
periods. However, a meta-analysis of clinical trials has shown that,
relative to placebo, SSRIs signiﬁcantly decrease depressive symptom-
atology after 1 week of treatment (Taylor et al., 2006) and indeed the
effect size of active treatment relative to placebo is numerically
greater during the ﬁrst week of therapy than in subsequent weeks.
Further, it has been demonstrated in healthy volunteers that 7 days
treatment with reboxetine produces positive biases in measures of
emotional perception and memory, suggesting that therapeutically
relevant changes in neuropsychological function are indeed apparent




Forty healthy volunteers were randomised to receive 7 days oral
treatmentwith citalopram(20 mg/day, n=12), reboxetine (4 mg/b.i.d.,
n=13) or placebo (n=15), in a double blind between groups design.
Medication was taken twice a day, once in the morning and once in the
evening, to maintain blinding. Ethical approval was provided by the
Oxford Research Ethics Committee B andwritten informed consentwas
obtained from all participants before screening and after a complete
description of the study was given. Exclusion criteria for all subjects
were current or pastAxis-1disorder on theStructuredClinical Interview
for DSM-IV (Spitzer et al., 2004) and any contraindications to MRI e.g.
pacemaker, mechanical heart valve, hip replacement, metal implants.
None of the participants took current medication apart from the
contraceptive pill. Before drug administration and to ensure group
matching, baseline information was collected using a neuropsycho-
logical battery that included: Beck Depression Inventory (BDI) (Beck
et al., 1961), State-Trait Anxiety Inventory (STAI) (Spielberger, 1983),
Fawcett–Clarke Pleasure Scale (FCPS) (Fawcett et al., 1983), and
Snaith–Hamilton Pleasure Scale (SHAPS) (Snaith et al., 1995). Body
mass index (BMI) was also calculated for each volunteer. To assess the
effects of the treatment the following questionnaires were taken
before and after the treatment: Visual Analogue Scales (VAS) of
happiness, sadness, anger, disgust, alertness and anxiety; and the
State Anxiety Inventory (Spielberger, 1983).
Overall design
MRI-derivedmeasures of brain function, based onblood-oxygenation-
level-dependent (BOLD) contrast, were used to compare brain responses
at rest across the three drug groups and on the 7th day approximately 5 h
after the last treatment. The resting-state data were acquired after the
volunteers had completed both a reward/aversion task and a structuralscan (McCabe et al., 2010). Subjectswere instructed to lie in dimmed light
with their eyes open, think of nothing in particular, and not to fall asleep.
fMRI scan
Images were acquired with a 3.0-T VARIAN/SIEMENS whole-body
scanner at the Centre for Functional Magnetic Resonance Imaging at
Oxford (FMRIB), where T2* weighted EPI slices were acquired every 2
seconds (TR=2). Imaging parameters were selected to minimise
susceptibility and distortion artefact in the orbitofrontal cortex
(Wilson et al., 2002). Coronal slices (25) with in-plane resolution of
3×3 mm and between plane spacing of 4 mm were obtained. The
matrix size was 64×64 and the ﬁeld of view was 192×192 mm.
Acquisition was carried out during the resting scan yielding 150
volumes in total. An anatomical T1-weighted sequence with coronal
plane slice, thickness 3 mm and in-plane resolution of 1.0×1.0 mm
was also acquired to improve the registration process.
Analysis methods
Pre-processing
Data analysiswas carriedout using FSL tools (www.fmrib.ox.ac.uk/fsl)
(Smith et al., 2004). After discarding the ﬁrst four volumes to allow for
T1 equilibration effects, fMRI data analysis was carried out using FEAT
(FMRI Expert Analysis Tool) Version 5.98, part of FSL (FMRIB's Software
Library, www.fmrib.ox.ac.uk/fsl). The pre-processing included the fol-
lowing steps: motion correction (Jenkinson and Smith, 2001) non-brain
removal (Smith, 2002); spatial smoothing using a Gaussian kernel of full-
width at half maximum (FWHM) of 6.0 mm; grand-mean intensity
normalisationof the entire 4Ddataset by a singlemultiplicative factor and
high pass temporal ﬁltering (Gaussian-weighted least-squares straight
line ﬁtting, with sigma=75.0 s). fMRI volumes were registered to the
individual's structural scan and standard space images using FMRIB's




Based on a-priori hypothesis, we created seed ROIs for the right
dmPFC (18 34 29) and the left dmPFC (−24 35 28). These areas have
been shown to have increased connectivity within the default mode
network and the affective network in the recent resting-state
functional connectivity study in depressed patients by Sheline et al.
(2010). We used Wake Forest University Pickatlas tool in SPM5 to
create the dorsal nexus spheres of 10-mm radius. We also created
seed ROIs for the right nucleus accumbens (10 10−8), the subgenual
cingulate (2 22−18) and the right amygdala (24 −4 −18) as these
areas are part of the affective network and have been shown to be
modulated by the action of antidepressant drugs in our previous
studies (McCabe et al., 2010; Norbury et al., 2007). Further these areas
are speciﬁcally implicated in fMRI studies in depression (Botteron
et al., 2002; Drevets et al., 2002, 1997; Sheline et al., 2001). For the
subgenual cingulate cortex we used Wake Forest University Pickatlas
tool in SPM5 to create the sphere of 10-mm radius. The nucleus
accumbens and the amygdala spheres were created with the Harvard-
Oxford subcortical structural atlas probabilistic atlas (Kennedy et al.,
1998; Makris et al., 1999) so as to maximise the exact coverage of
these smaller differentially shaped structures, furthermore the
nucleus accumbens and the amygdala masks were thresholded by
20%.
Time series extraction and higher-level analysis
An FSL tool (Featquery) was used to extract the time series within
each of the ﬁve seed regions for each individual subject after having
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voxels in each seed ROI. Using the extracted time series we performed
multiple regression analysis using FMRI data processing FEAT. These
analyses produced separate individual participant-level correlation
maps of all voxels that were positively or negatively correlated with
each of the ﬁve seeds. Afterwards, higher level (group level) analysis
was carried out using FMRIB's Local Analysis of Mixed Effects (FLAME)
(Woolrich et al., 2004). The general linear model (GLM) was applied
to test for group averages and differences among the three groups
(citalopram, reboxetine and placebo). The Z statistic images were
thresholded using clusters determined by ZN2.3, and a whole brain
family-wise error-corrected cluster signiﬁcance threshold of pb0.05
was applied to the superthreshold clusters. Graphs of % BOLD signal
change (Figs. 1–3) were created with the FSl tool, Featquery (www.
fmrib.ox.ac.uk/fsl) (Smith et al., 2004).
Nuisance signal regression
In order to account for potential indeterminate noise, nine
covariates of no interest (nuisance) were identiﬁed for inclusion in
our analyses. In detail, global signal, white matter (WM), cerebrospi-
nal ﬂuid (CSF), and the 6 motion parameters for each individual were
added. As the global signal is thought to reﬂect a combination of
physiological processes (such as cardiac and respiratory ﬂuctuations)
and scanner drift, it was included as a nuisance signal to minimise
the inﬂuence of such factors (Birn et al., 2006; Gavrilescu et al., 2002;
Macey et al., 2004). In order to extract the nuisance covariate
time series for WM and CSF, we ﬁrstly segmented each individual's
high-resolution structural image, using FSL's FAST segmentation
program. The resulting segmented WM and CSF images were then
thresholded to ensure 80% tissue type probability. These thresholded
masks were then applied to each individual's time series, and a mean
time series was calculated by averaging across all voxels within the
mask (Fox et al., 2005).
Results
Demographic details and mood ratings
There were no signiﬁcant differences among the three groups as
determined by one-way analyses of variance (ANOVAs) for age,
gender or body mass index, pN0.06 (Table 1). There were no
signiﬁcant differences between the three groups as determined by
one-way ANOVAs for measures of anhedonia (Snaith–HamiltonFig. 1. Coronal and sagittal slices showing amygdala seed region, functional connectivity ma
seed region and a graph of the % BOLD signal change extracted from the cluster of signiﬁcaPleasure Scale, Fawcett–Clarke Pleasure Scale) trait anxiety (TRAIT)
or mood (Beck Depression Inventory), pN0.1 (Table 1). Treatment
with reboxetine or citalopram also failed to affect subjective state and
mood measured over the 7-day experimental period on visual
analogue scales (alertness, disgust, drowsiness, anxiety, happiness,
nausea, and sadness) as determined by repeated-measures ANOVAs,
pN0.1 (Table S1 in Supplement 1).
Functional connectivity: placebo
For each of the ﬁve seed regions previously associated with
depression and the effects of antidepressant medications on neural
processing, seed-based correlation analyses were employed to
characterise their associated functional systems during rest. The
functional connectivity for the ﬁve seed regions is described in
Supplementary Table 2 for the placebo group alone (baseline). Overall,
the patterns of connectivity associated with each of the seed regions
are consistent with other neuroimaging studies examining the
correlations between these seed regions and other brain areas in
resting-state and functional connectivity experiments in healthy
controls and depressed patients (Anand et al., 2005b; Bluhm et al.,
2009; Fox and Raichle, 2007; Frodl et al., 2010; Greicius et al., 2007;
Raichle et al., 2001; Raichle and Snyder, 2007; Zhou et al. 2010).
Functional connectivity: drug vs. placebo
Amygdala seed
Compared to the placebo group there was reduced functional
connectivity between the amygdala and the ventral medial prefrontal
cortex (vmPFC) in the citalopram group compared to placebo (Fig. 1).
There was also reduced functional connectivity between the amyg-
dala and the OFC in the reboxetine group compared to placebo (Fig. 2)
(Table 2).
Nucleus accumbens seed
Compared to the placebo group there was reduced functional
connectivity between the nucleus accumbens and the mid OFC in the
reboxetine group (Fig. 3). There were no differences between the
placebo and the citalopram group for this seed region (Table 2).
dmPFC seed
There were no differences between the placebo and the reboxetine
group for this seed region. Compared to the placebo group there was
reduced functional connectivity between the dmPFC seed region andps for the placebo and citalopram groups, the group difference in connectivity with the
nt difference between the groups [vmPFC −6 46 −10 p=0.04].
Fig. 2. Coronal and sagittal slices showing amygdala seed region, functional connectivity maps for the placebo and reboxetine groups, the group difference in connectivity with the
seed region and a graph of the % BOLD signal change extracted from the cluster of signiﬁcant difference between the groups [OFC −26 28 −8 p=0.0002]. Bars indicate SEM.
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McCabe et al., 2011).
Subgenual seed
Therewere no differences between the placebo group and either of
the drug groups citalopram or reboxetine in subgenual functional
connectivity.
Discussion
Our study reveals that 7 day administration with the antidepres-
sants citalopram and reboxetine modulates resting-state functional
connectivity in a double-blind placebo controlled design in healthy
volunteers. Speciﬁcally, resting-state functional connectivity was
reduced between the prefrontal cortex and the amygdala for both
the reboxetine and the citalopram groups. Further there was reduced
connectivity between the OFC and the striatum in the reboxetine
group compared to the placebo group. Consistently previous studies
using task related functional MRI have also shown these limbic areas
to be modulated by citalopram and reboxetine (McCabe et al., 2010)
and previous studies of resting-state functional connectivity in
depressed patients reveal dysfunction in these regions (Anand et al.,
2005a; Cullen et al., 2009; Greicius et al., 2007; Zhou et al., 2010).Fig. 3. Coronal and sagittal slices showing nucleus accumbens seed region, functional connec
with the seed region and a graph of the % BOLD signal change extracted from the cluster oUnlike our previous ﬁnding of reduced dmPFC connectivity with the
hippocampus in the citalopram group compared to placebo (McCabe
et al., 2011) we found no effects on connectivity with the dmPFC for
the reboxetine group. We also found no effects of the antidepressants
on connectivity with the subgenual cingulate cortex.
In our study both antidepressants reduced connectivity between
the amygdala and parts of the prefrontal cortex. Such effects are
potentially relevant to the treatment of depression as a number of
task related studies have revealed reduced amygdala activity after
antidepressant drug treatment (Harmer et al., 2006; Murphy et al.,
2009; Norbury et al., 2007; Sheline et al., 2001) in healthy and
depressed volunteers. Furthermore a recent study by Versace et al.
(2010) revealed that depressed and bipolar patients were associated
with increased amygdala-orbitofrontal cortex connectivity compared
to healthy controls. Also the patients currently treated with antide-
pressants had reduced functional connectivity in these areas (Versace
et al., 2010) and the authors concluded that the increased connectivity
may serve as a state marker for depression. Our results indicate that
using a randomised placebo controlled design we were able to extend
these ﬁndings to resting-state functional connectivity in healthy
volunteers with antidepressant treatment and we suggest that the
normalisation of connectivity could be the direct result of the
pharmacological treatment.tivity maps for the placebo and reboxetine groups, the group difference in connectivity
f signiﬁcant difference between the groups [OFC 26 20 −12 p=0.03].
Table 1
Group demographic and psychosocial measures.
Measure Citalopram Reboxetine Placebo
(n=12) (n=13) (n=15)
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Age, years 25.5 (5) 26 (3.8) 25.2 (5)
Gender M=6, F=6 M=5, F=8 M=7, F=8
BDI 2.8 (3.4) 1.3(1.8) 1.2 (1.2)
TRAIT 34 (5.9) 32.6 (7.6) 31.7 (4.8)
FCPS 126 (13) 140 (14) 136.6 (14)
SHAPS 23.7 (4) 22 (4.8) 19.9(5.7)
BMI 24.4(3.5) 21.8(2.3) 24(2.8)
BDI, Beck Depression Inventory; FCPS, Fawcett–Clarke Pleasure Scale; SHAPS, Snaith–
Hamilton Pleasure Scale; TRAIT, State-Trait anxiety inventory; BMI, Body Mass Index.
One-way ANOVAs all pN0.06.
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striatum was reduced with reboxetine treatment during our resting-
state scan. The striatum has been implicated previously in studies on
resting-state functional connectivity in depression (Bluhm et al.,
2009; Greicius et al., 2007) and a recent study in depressed patients
found that there was increased functional connectivity in the
striatum, the amygdala and the hippocampus during negative
emotional processing (Hamilton and Gotlib, 2008). The authors
concluded that depressed individuals over-recruit neural networks
involved more generally in enhancing memory for affective stimuli
and that the degree to which they over-recruit this system is related
to the severity of clinical symptomatology (Hamilton and Gotlib,
2008). Our results are the ﬁrst to show that these areas which are
known to be involved in the affective salience of stimuli, the
representation of reward value and self-referential processing can
be modulated by currently used antidepressant medications outside
of a task situation and in unmedicated healthy control volunteers.
The OFC/vmPFC has been described as the principal mediator in a
reciprocal relationship between the subcortical–cortical regions in
depression (Seminowicz et al., 2004) and a recent study has revealed
aberrant mutual excitation between the medial prefrontal cortex and
part of the ventral anterior cingulate in depressed patients which also
positively correlated with increased scores on a depressive rumina-
tion scale (Hamilton et al., 2010). This region is very close to the
region of vmPFC that we have found to have reduced connectivity
with the amygdala in the citalopram group (Table 2). As the medial
PFC has been reported to underlie the evaluation of the self (Gusnard
et al., 2001; Northoff and Bermpohl, 2004) it has been hypothesised
that over activity in this region might be responsible for the
maladaptive rumination seen in depression (Hamilton et al., 2010).Table 2









NAcc seed [10, 10,−8]
PlaceboNReboxetine
OFC (R) 26 20 −12 3.84 0.03
Amygdala seed [24,−4,−18]
PlaceboNCitalopram
vmPFC (L) −6 46 −10 2.85 0.04
PlaceboNReboxetine
OFC (L) −28 26 −8 3.66 0.0002
LOFC (L) −44 20 −6 3.66 0.0002
R, right; L, left; vmPFC, ventral medial prefrontal cortex; LOFC, lateral orbitofrontal
cortex; OFC, orbitofrontal cortex; NAcc, Nucleus accumbens; p-values clusters whole
brain fully corrected (FWE pb0.05).Furthermore a recent study by Frodl et al. (2010) discusses how the
integrative function of the OFC with its convergence of connections
from the subcortical limbic regions is a key player in the pathophys-
iology of major depression (Frodl et al., 2010). Disrupted connectivity
between the vmPFC/OFC and regions outlined here such as the amyg-
dala and the striatum may thus underlay the aberrant negative and
positive emotional processing witnessed in depression. Speciﬁcally
related to the recent Sheline et al. (2010) study on resting-state
functional connectivity in depressed patients we have previously
examined the dmPFC (dorsal nexus) as a seed region and found that
the antidepressant citalopram reduced the connectivity between the
dmPFC and a part of the default mode network the hippocampus in
our healthy volunteers, we concluded that antidepressant medica-
tions may work by reducing the aberrant increased connectivity seen
in depression (McCabe et al., 2011). Interestingly though in this study
we did not ﬁnd any effects of reboxetine on dmPFC connectivity. This
may simply be due to power and perhaps with increased numbers of
volunteers differencesmay have been revealed. Or it could also be due
to the relatively less efﬁcacious nature of reboxetine as a treatment for
depression (Cipriani et al., 2009; Eyding et al., 2010). Although we ran
our resting-state approximately 10–15 min after a task it is possible
that examining resting-state after other tasks could effect the results
and thus we intend for future experiments to run resting-state scans
before any other tasks.
As hypothesised reboxetine decreased mesolimbic striatal–OFC
connectivity (indicating catecholaminergic pathway involvement)
whereas citalopram decreased amygdala-vmPFC connectivity ((and
in our previous study hippocampal–dmPFC connectivity) indicating
serotonergic pathway involvement). These results are consistent with
recent studies in animals using pharmacological challenges to unpick
rat brain connectivity. Schwarz and colleagues examined pharmaco-
logical challenges such as amphetamine (catecholamine) and ﬂuox-
etine (SSRI) on rat brain functional connectivity. Similarly they report
that catecholaminergic drugs modulate striatal and prefrontal
connections whereas serotonergic drugs modulate hippocampal,
amygdala and thalamus connections (Schwarz et al., 2009; Schwarz
et al., 2007a,b). Yet this is the ﬁrst examination, to the best of our
knowledge, of the effects of SSRI and SNRI antidepressant drug action
in the resting human brain. Similar to Schwarz et al. we also found
that the regions affected by the drugs closely reﬂect the known
pathways in the neurotransmitter systems targeted by these drugs.
Further work on receptor mapping would of course also aid our
understanding of the brains architecture and would be especially
relevant for pharmacological studies such as this (Zilles and Amunts,
2009).
There was no effect of either of the antidepressant medications on
connectivity with the subgenual cingulate cortex seed, despite reports
of increased subgenual connectivity in depressed patients resting-
state data (Sheline et al., 2010). The subgenual cingulate cortex is an
important area targeted in deep brain stimulation for treatment-
resistant depression (Kennedy et al., 2011; Lozano et al., 2008;
Mayberg et al., 2005) perhaps then antidepressant improvement may
lie in the development of drugs that can better target regions such as
the subgenual cingulate cortex as well as the dmPFC (Sheline et al.,
2010). The subgenual cingulate is also a region that is hard to image
and thus it cannot be ruled out that our results might in some way
reﬂect signal drop-out in this area.
In conclusion, the results from this study show that both serotoner-
gic and noradrenergic antidepressants decrease resting-state functional
connectivity in areas of the brain that correspond with the central
activity of these drugs. The results also support our hypothesis that
antidepressant medications may work by rebalancing cortical control
in depression. It will be of great interest to examine resting-state
functional connectivity in unmedicated depressed patients before
and after antidepressant treatment as the next step in unravelling
antidepressant drug action at the neural level.
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